Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HWK-007 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on HWK-007, a putative antibody-drug conjugate (ADC) targeting PTK7 (Mar 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HWK-007 | HWK007|HWK 007 | PTK7 Antibody 6 | Limited information is currently available on HWK-007, a putative antibody-drug conjugate (ADC) targeting PTK7 (Mar 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07444814 | Phase I | HWK-007 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |